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Human serum albumin (HSA) is an abundant carrier protein present in the blood plasma manifesting affinity for drugs 
and ligands. The bindings of several drugs can cause changes in the structural conformation of HSA that may affect its 
function. HSA is also known to in vitro form amyloid-like aggregates with fibrillar morphology as observed under TEM. 
Earlier, we showed that the HSA amyloid-like aggregates display self-seeding potential and detergent stability and the 
dimers of HSA, which are preferable for clinical applications due to their longer circulatory life, can also form amyloid-like 
aggregates. As aspirin, a commonly prescribed drug, was previously documented to acetylate HSA at one of its lysine 
residues, here, we examined if acetylation has any effect on the in vitro amyloid-like aggregation of HSA. We show that 
HSA acetylated in vitro using acetylsalicylic acid manifests relatively reduced levels of amyloid-specific properties such as 
turbidity, Thioflavin-T-positive aggregation, -sheet content and stability against an ionic detergent. Also, TEM imaging 
shows that the acetylated HSA forms relatively less aggregates and with smaller sizes whereas, the aggregates of HSA are 
more abundant and larger in sizes with fibrillar morphology which further supports that acetylation can attenuate the 
amyloid-like aggregation of HSA. 
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Human serum albumin (HSA), a predominant plasma 
protein in the blood, is a globular protein with a 
predominantly alpha helical structure1.  HSA binds to 
and aids in the transport of several endogenous 
metabolites such as bilirubin and fatty acids and 
also exogenous molecules including nutrients and 
drugs. HSA also helps in the maintenance of 
osmolarity and manifests antioxidant properties2. 
Changes in the physiological levels of HSA such as, 
hyperalbuminemia as well as hypoalbuminemia can 
be a symptom of liver pathologies. HSA is also used 
as an adjunct with other therapies to treat critical 
conditions under certain circumstances like acute lung 
injury in patients with hypo-proteinemia3. 
The sequence of the functional HSA consists of 
585 amino acids with a single tryptophan residue 
present at 214. As part of its secondary structure HSA 
contains about 67% α-helices, which are divided into 
three domains with each domain consisting of two 
sub-domains A and B. Structure of HSA has two high 
affinity drug binding sites. Of these, the site-1 is a 
hydrophobic pocket formed in the subdomain A of the 
second domain and it is a characterized binding site 
for drugs such as warfarin and acenocoumarol4. The 
entrance of the pocket has positively charged residues 
and the hydrophobic pocket involves a lone 
tryptophan at position 214. Because of its high 
affinity for the drug binding, the pharmacokinetics of 
HSA and the accompanying alterations in the 
conformation of the HSA molecule have been of 
considerable interest5. Changes in the conformation of 
HSA due to the binding of drug molecules including 
ciprofloxacin and tofacitinib have been well 
characterized6,7. 
Acetylsalicylic acid, or aspirin, is a commonly 
prescribed drug molecule which is known to interact 
with lysine residues of HSA in vitro as well as 
in vivo8,9. Previous studies from patients have reported 
that the ingestion of therapeutic doses of aspirin can 
cause permanent acetylation of HSA and coherent 
observations have also been made in vitro under 
physiological conditions9,10. In fact, previous studies 
have shown that the aspirin mediated modification of 
lysine-199 of HSA affects its esterase activity as well 
as its binding to several other drug molecules11,12.  
Several proteins are involved in causing 










form amyloid-like aggregates in vitro that typically 
display beta-sheet rich conformation13-18. Amyloid 
proteins can cause cytotoxicity via several mechanisms 
such as by blocking proteosomes and causing oxidative 
stress19-21. Notably, post-translational modifications 
including acetylation have been known to modulate the 
amyloid-like aggregations of several proteins including 
the TDP-43 protein involved in the amyotrophic lateral 
sclerosis (ALS) disease and the Tau protein involved in 
the Alzheimer’s disease22-24. HSA protein has been 
previously shown to form amyloid-like fibrillar 
aggregates in vitro25,26. In this study, we have examined 
the effect of acetylation on the amyloid-like aggregation 
of HSA using thioflavin-T binding assay, detergent 
stability assay, -sheet content estimation and TEM 
imaging. 
 
Materials and Methods 
 
Materials  
HSA protein expressed recombinantly in 
Saccharomyces cerevisiae was purchased from Sigma, 
USA. Thioflavin-T, Sodium dodecyl sulphate (SDS) and 
N-Lauroylsarcosine sodium salt (sarkosyl) were 
procured from Sigma–Aldrich, USA. Acrylamide, 
Agarose, Sodium salicylate, acetyl salicylic acid 
(aspirin), Coomassie brilliant blue, β-mercaptoethanol, 
sodium chloride, sodium phosphate dibasic and 
monobasic were purchased from Himedia, India. 
Methanol was purchased from SRL, India. 
 
Aspirin-mediated acetylation of HSA  
Acetylation of 15 mg/mL HSA was carried out 
using a working concentration of 1.5 mM aspirin 
prepared from a stock solution of 10 mM concentration 
and it was incubated for 24 h at 37C, after which the 
unreacted aspirin was removed by dialysing against  
10 mM phosphate buffer saline containing 0.01 M 
salicylic acid for 12 h at 4C. This was followed by 
dialysing against 10 mM phosphate buffer twice for  
12 h each at 4C to make sure all the free aspirin was 
removed. This acetylated HSA was checked for its 
concentration and used for further experiments10.  
 
SDS-PAGE 
HSA protein after the acetylation reaction was 
analyzed on 10% SDS-PAGE to eliminate the 
possibility of any protein degradation before usage in 
further studies. The wild-type HSA protein was also 
electrophoresed for comparison. Samples were either 
treated with non-reducing or reducing Laemmli 
sample buffer before the electrophoresis27. 
Amyloid-like in vitro aggregation of HSA  
10 mg/mL of acetylated HSA orwild-type HSA 
proteins were solubilised in 10 mM sodium phosphate 
buffer (pH 7.4) with 50 mM NaCl. For inducing the 
amyloid-like aggregation, HSA or acetylated HSA 
was incubated at 65°C up to 50 h without shaking. 
After the 24 h or 50 h of incubation, assays to assess 




Turbidity as a measure of protein aggregation was 
assessed by recording absorbance of the HSA samples 
at 350 nm at various time-points of incubation from  
0 to 50 h29.  
 
Thioflavin-T binding assay 
Thioflavin-T (ThT) dye is known to bind selectively 
to amyloid aggregates which significantly alters its 
fluorescence properties30. 70 μL of aggregated sample 
was added with 2 μL of ThT (stock concentration:  
30 mM) and ThT fluorescence spectra were recorded in 
Perkin Elmer Enspire multimode plate reader. The ThT 
fluorescence excitation spectra were recorded from  
250-460 nm wavelengths by fixing the emission at  
495 nm. Then, the emission spectra were recorded 
from the wavelength 460-600 nm after fixing the 
excitation wavelength at 450 nm. 
 
Visualization of Thioflavin-T-positive aggregates by 
fluorescence microscopy 
For visualization of the ThT-stained HSA or 
acetylated HSA protein aggregates, 10 μL of HSA or 
acetylated HSA samples incubated at 65°C for 24 h or 
50 h were observed under 10x objective lens using the 
GFP filter of Leica DM2500 fluorescence microscope31. 
Fluorescence images were further processed for colour 
using the ImageJ software32. 
 
Far-UV CD spectroscopy 
Proteins undergo changes to -sheet rich structural 
conformation upon amyloid-like aggregation17,29. To 
analyze the secondary structure of HSA or acetylated 
HSA before and after aggregation, the samples were 
transferred to a quartz CD cuvette of path length  
2 mm and the far-UV CD spectra were recorded from 
wavelength 260-190 nm using Jasco 1500 
spectropolarimeter. Freshly prepared HSA and 
acetylated HSA monomers dissolved in the 
aggregation buffer or their aggregated versions after 
50 h incubation were used to record far-UV CD 
spectra. The results were expressed as mean residue 
ellipticity [ϴ]MRE. Next, relative secondary structural 




contents were estimated using the online secondary 
structure prediction server Dichro Web using the 
algorithm CONTIN and the set SP175 optimized for 
the 190-240 nm range33. 
 
Semi-denaturing detergent agarose gel electrophoresis  
(SDD-AGE) 
Aggregations of prion and amyloid proteins confer 
stability against disaggregation by ionic detergents 
such as SDS and sarkosyl18,25,34,35. For examining their 
stability against sarkosyl, HSA and acetylated HSA 
aggregates were first treated with 1% sarkosyl for  
10 min at room temperature and then they were mixed 
with non-reducing Laemmli sample buffer devoid of 
any detergent followed by electrophoresis on 1% 
agarose gel. Then, the agarose gel was stained using 
Coomassie dye for visualization of the protein 
monomers and their aggregates. 
 
Transmission electron microscopy (TEM) 
A high-resolution transmission electron microscope 
(JEOL, JEM 2100, U.S.A), operated at 200 kV was 
used to acquire the electron micrographs of HSA and 
acetylated HSA protein aggregates. The protein 
aggregate suspension was dropped on a Holey carbon-
coated grid and then air dried for 10 min. Then, the 
protein sample was negatively stained for 20s with 
2% uranyl acetate and allowed to dry overnight before 
capturing the TEM images.  
 
Results and Discussion 
 
Acetylation of HSA affects its amyloid-like aggregation 
For examining the effect of acetylation on the 
amyloid aggregation of HSA, we first acetylated HSA 
by incubating HSA with aspirin at a molar ratio of 
1:1.5 (protein: aspirin) for 24 h at 37C and removed 
the excess of unbound aspirin by dialysis36. After 
dialysis, the HSA and acetylated-HSA proteins were 
examined using 10% SDS PAGE under both reducing 
and non-reducing conditions. We found that the 
acetylated HSA retained structural integrity similar to 
that of the un-acetylated HSA protein as both forms of 
the protein showed similar slower mobilities under the 
reducing conditions compared to the non-reducing 
conditions which suggests of opening of their 
structures in presence of a reducing agent via the 
reduction of their disulfide bonds (Fig. 1A). Notably, 
the HSA protein contains 17 disulfide bridges in its 
structure. 
To study the effect of the lysine acetylation on the 
amyloidogenicity of HSA, we incubated the 
acetylated HSA at the optimal aggregation 
temperature of 65°C for 50 h and then examined the 
formation of amyloid-like aggregates. For this, we 
first examined the turbidity of the acetylated and non-
acetylated HSA aggregates which can report on their 
aggregation status. The turbidity of the HSA 
aggregates, as recorded by absorbance at 350 nm, was 
higher than the aggregates of the acetylated HSA both 
at 24 h and 50 h of incubations (Fig. 1B). Next, we 
examined the aggregation status of HSA and 
acetylated HSA samples by recording the emission 
and excitation spectra of the amyloid binding dye, 
thioflavin T (ThT) upon addition to these protein 
samples. When excited at 450 nm, the HSA sample 
showed increased ThT emission fluorescence at  
495 nm thereby indicating the formation of amyloid-
like aggregates (Fig. 1C). In comparison to the HSA 
sample, the ThT fluorescence emission at 495 nm was 
significantly reduced in the acetylated HSA sample 
(Fig. 1C). Likewise, the acetylated HSA sample also 
manifested lesser fluorescence intensity at 450 nm in 
the ThT excitation spectra (Fig. 1C). Taken together, 
the data suggest that acetylation decreases the 
amyloid-like aggregation of HSA.  
 
Acetylated HSA forms smaller thioflavin-T-positive 
aggregates with diminished detergent stability 
Next, we examined the ThT-stained aggregates of 
HSA and acetylated HSA under the GFP filter of the 
fluorescence microscope to visualize the ThT-positive 
fluorescent protein speckles as an indication for 
amyloid-like aggregation31. For this, samples of the 
acetylated and non-acetylated HSA proteins after 
incubation at 65°C in aggregating conditions, were 
transferred on a glass slide and images were taken 
using 10x objective lens under GFP filter. After 24 h 
of incubation, we were able to detect green 
fluorescent speckles in the HSA samples where the 
majority of the species frequently observed were with 
irregular margins and relatively bigger sizes. On the 
contrary, in the acetylated HSA sample, we observed 
relatively lesser number of ThT-positive speckles 
which were also of relatively smaller sizes (Fig. 2). 
After 50 h of incubation, an increase in the sizes of 
the aggregates in both the HSA and acetylated HSA 
samples were observed. However, the HSA samples 
manifested clustered and relatively bigger size 
fluorescent speckles compared to the acetylated HSA 
samples. This data is consistent with the observed 
reduction in the intensity of the ThT emission and 
excitation fluorescence for the acetylated HSA 




relative to the non-acetylated HSA (Fig. 1C) and 
supports that acetylation mitigates the 
amyloidogenicity of HSA.  
Amyloid protein aggregates are known to show 
enhanced stability against ionic detergents including 
SDS and sarkosyl18,25,34,35. Previously, the aggregates of 
HSA were also found to display stability to sarkosyl25. 
Therefore, we examined the relative stabilities of HSA 
and acetylated HSA amyloid-like aggregates in 
presence of sarkosyl at room temperature using  
semi-denaturing detergent agarose gel electrophoresis 
(SDD-AGE)which can analyze protein aggregates of 
even more than 3000 kDa molecular weight18,25,34,35. 
The non-aggregated samples of both the HSA and 
acetylated HSA, as expected, displayed only monomers 
when analyzed on SDD-AGE using 1% sarkosyl 
treatment at room temperature and electrophoresis on 
1% agarose gel. Consistent with our previous 
observations25, the HSA aggregates retained larger 
sizes and majority of the protein failed to enter the gel 
and was retained in the loading well thereby suggesting 
presence of very high molecular weight 1% sarkosyl-
resistant aggregates. In addition, a fraction of HSA 
aggregates were broken to high molecular weight 
aggregates that were electrophoresed in the gel as faint 
smear thereby also suggesting that the HSA aggregates 
are resistant to complete disaggregation by 1% sarkosyl 
treatment at room temperature (Fig. 3). In contrast,  
we observed that the acetylated HSA aggregates were 
not trapped in the loading well and rather were able to 
enter the gel and showed some sarkosyl-stable 
aggregates of moderate sizes in addition to manifesting 
a prominent monomeric protein band which suggests 
of relatively weaker stability to the 1% sarkosyl 
treatment as compared to the HSA aggregates (Fig. 3). 
Taken together, the data support that the acetylation  
of HSA causes a decrease in the ionic detergent 
stability of the in vitro-made aggregates thereby 
indicating a mitigation of the amyloid nature of the 
acetylated HSA aggregates. 
 
Acetylated HSA aggregates manifest relatively lesser -sheet 
content 
As amyloid-like aggregations of several proteins 




Fig. 1 — Acetylation of HSA affects its amyloid-like aggregation. (A) 10% SDS-PAGE of HSA and acetylated HSA monomers was
performed under reducing (R) and non-reducing (NR) conditions; (B) The turbidity of the HSA and acetylated-HSA samples incubated
under aggregation conditions was examined by measuring absorbance at 350 nm; (C) Amyloid-aggregation in HSA and acetylated HSA
was induced by incubation for 50 h at 65°C followed by addition of thioflavin-T (ThT) dye before recording the ThT emission spectra
(excitation: 450 nm) and the ThT excitation spectra (emission: 495 nm) 
 




a predominantly -sheet rich conformation16,17,35, 
therefore by recording the far-UV CD spectra we next  
analysed if the aggregates of HSA and the acetylated 
HSA differ in their relative -sheet contents. Similar 
to the previous reports, the far-UV CD spectrum of 
the monomeric HSA showed two characteristic 
negative peaks at 208 nm and 222 nm thereby 
indicating a predominantly alpha helical secondary 
structure37 (Fig. 4A). The far-UV CD spectrum of the 
monomeric acetylated HSA also displayed two 
characteristic peaks at 208 and 222 nm and a similar 
overall shape but with altered amplitude compared  
to the non-acetylated HSA far-UV CD spectrum  
(Fig. 4A). The far-UV CD spectra of the aggregated 
HSA and the aggregated acetylated HSA manifested 
differences in the trend compared to their respective 
monomeric proteins. The shape of the aggregated 
HSA far-UV CD spectrum was observed to be similar  
to as reported previously37. Notably, there was a 
marked difference between the shapes of the far-UV 
CD spectra of the aggregated HSA and the aggregated 
acetylated HSA samples (Fig. 4A). Furthermore, 
when these spectra were used for secondary structural 
predictions using Dichro Web, the relative contents of 
the -helix and -sheet in the monomeric HSA and 
the monomeric acetylated HSA were found to be 
different indicating alterations in the protein 
conformation upon acetylation (Fig. 4B). Acetylation 
of lysine residues in proteins can cause the net charge 
on the protein molecule to be more negative and 
charge-charge repulsions can affect the folding and 
structure of an acetylated protein. The observed 
difference in the secondary structural content of the 
acetylated HSA relative to the non-acetylated HSA 
suggest some perturbation in the charge balance in the 
protein structure upon acetylation. Notably, the 
aggregates of HSA manifested relatively higher 
percentage of -sheet secondary structure when 
compared with the aggregates of the acetylated HSA 
thereby suggesting that acetylation reduces the 




Fig. 2 — Fluorescence micrographs of thioflavin-T-positive speckles
of HSA and acetylated HSA aggregates. Thioflavin-T (ThT)-positive
amyloid-like aggregates were examined using GFP filter of a
fluorescence microscope under 10x objective lens after 24 h or 50 h of
incubation of the HSA and acetylated HSA samples under
aggregating conditions. The sizes of the ThT-positive speckles in the
aggregated HSA samples are comparatively bigger than those from




Fig. 3 — Assessment of detergent stabilities of the HSA and
acetylated HSA aggregates by SDD-AGE. Relative stability of the 
pre-formed aggregates of the HSA and acetylated HSA proteins
against the ionic detergent sarkosyl was assessed by using semi 
denaturing detergent agarose gel electrophoresis (SDD–AGE). 
The samples were treated with 1% sarkosyl for 10 min at
room temperature and then electrophoresed on 1% agarose gel
and visualized for protein by Coomassie staining. Lane 1: 
HSA monomer (70 g protein); Lane 2: Acetylated HSA
monomer (70 g protein); Lane 3: HSA amyloid (240 g protein); 
Lane 4: Acetylated HSA amyloid (240 g protein) 




TEM images manifest smaller and some with globular 
morphology acetylated HSA aggregates  
Transmission electron microscopy (TEM) has been 
widely used for studying the morphological and 
structural features of the amyloid fibrils38. Thus, we 
examined if the aggregates of HSA and acetylated 
HSA differ in their morphological features. For this, 
the HSA and the acetylated HSA samples incubated 
for 24 h under optimal temperature of 65°C were 
examined under TEM after negative staining with 
uranyl acetate. Consistent with the earlier reports, we 
observed elongated and fibrillar morphology in the 
aggregated HSA sample thereby confirming of its 
amyloid-like aggregation (Fig. 5)26. In contrast, when 
we examined the acetylated samples in TEM, the 
aggregates were sparse, lacked fibrillar morphology 
and were significantly smaller in dimensions (Fig. 5). 
Taken together, the TEM imaging data confirm that 
acetylation modulates and decreases the in vitro 
amyloidogenicity of the HSA protein. This decrease 
in the amyloidogenicity of the acetylated HSA may be 
due to the structural changes in the monomeric protein 
upon acetylation, as revealed by the far-UV CD 
spectroscopy, that may make it less aggregation-
competent or due to the unmasking of the negative 
charges upon the neutralization of the positive charge on 
the lysine residue after the acetylation of its side-chain 
which would cause inter-molecular repulsions during the 
amyloid aggregation or due to a combination of both of 
these effects. This study adds to the widely ongoing  
in vitro and in vivo studies on model proteins for 
structure-function and role in diseases39,40.   
 
Conclusion 
In physiological conditions, the microenvironment 




Fig. 4 — Far-UV CD spectra of monomeric and aggregated HSA
and acetylated HSA. (A) Far-UV CD spectra of the monomeric
HSA and the acetylated HSA freshly solubilized in the
aggregation buffer were recorded immediately and the results
have been depicted in terms of mean residue ellipticity [ϴ]MRE. 
Pre-formed HSA and the acetylated HSA aggregates from the
50 h of incubation under aggregating conditions, were diluted in
the aggregation buffer and their far-UV CD spectra were
recorded. The far-UV CD spectrum of the HSA amyloid has been
magnified in the inset to clearly show the shape of the
spectrum;(B) Secondary structure predictions using Dichro Web
prediction tool from the far-UV CD spectra from panel A are




Fig. 5 — TEM micrographs of HSA and acetylated HSA
aggregates. Amyloid aggregations of HSA and acetylated HSA
were induced by incubating at 65 °C for 24 h and the samples
were examined under TEM. The TEM images of the HSA
amyloid aggregates negatively stained with uranyl acetate show
larger aggregate with fibrillar morphology (indicated by blue 
arrows). In contrast, the acetylated HSA sample lacks fibrillar
species and rather it manifests aggregates that are short, irregular
and raft-like (indicated by yellow arrows) 




of HSA. As HSA acts as a drug-carrier, examining  
the effects of drug molecules on its structure or  
its propensity to aggregate are important towards  
its applications. Earlier, HSA has been shown to  
be acetylated in patients taking the aspirin drug  
and HSA can also get acetylated in vitro. In the 
current study, we examined the effect of acetylation 
on the amyloidogenicity of HSA and found that  
the acetylation of HSA can reduce the in vitro 
amyloid-like aggregation of HSA as evident by the 
lesser extent of thioflavin-T binding, lesser -sheet 
content, reduced ionic detergent stability and 
relatively smaller size aggregates as visualized by 
TEM imaging.  
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